TY - JOUR
T1 - Serum selenoprotein P, but not selenium, predicts future hyperglycemia in a general Japanese population
AU - Oo, Swe Mar
AU - Misu, Hirofumi
AU - Saito, Yoshiro
AU - Tanaka, Mutsumi
AU - Kato, Seiji
AU - Kita, Yuki
AU - Takayama, Hiroaki
AU - Takeshita, Yumie
AU - Kanamori, Takehiro
AU - Nagano, Toru
AU - Nakagen, Masatoshi
AU - Urabe, Takeshi
AU - Matsuyama, Naoto
AU - Kaneko, Shuichi
AU - Takamura, Toshinari
N1 - Funding Information:
Competing Interests: Dr. Misu received a commercial research grant from Novartis Pharma and has received speakers’ bureau honoraria from Merck & Co. and Boehringer Ingelheim Co. The other authors have no potential conflicts of interests.
Funding Information:
This work was supported by the following grants: JSPS KAKENHI Grant Numbers 25461334 (H.M.), 16K09740 (H.M.); and JST Adaptable and Seamless Technology transfer Program (A-STEP) Grant Numbers AS2311400F and 15im0302407 (H.M., Y.S., M.T.).
Publisher Copyright:
© 2018, The Author(s).
PY - 2018/12/1
Y1 - 2018/12/1
N2 - We aimed to test the hypothesis that selenoprotein P (SELENOP), a hepatokine involved in the development of both insulin resistance and impaired insulin production in mice, is related to future onset of hyperglycemia in humans. 76 healthy non-pregnant human subjects without diabetes underwent oral glucose tolerance test (OGTT) at baseline and 4-years follow-up. Nine subjects developed either impaired glucose tolerance or type 2 diabetes at follow-up. At baseline, SELENOP concentrations correlated negatively with insulinogenic index, but not with homeostasis model assessment-estimated insulin resistance (HOMA-IR). Multivariate analysis showed that baseline SELENOP predicted fasting plasma glucose at follow-up independently of the other parameters. The receiver operating characteristic (ROC) curve analysis showed that baseline concentrations of serum SELENOP, but not of selenium, were a reliable test to predict future onset of glucose intolerance. In conclusion, elevation of circulating SELENOP, but not of circulating selenium, was positively and independently associated with future onset of glucose intolerance in a general Japanese population.
AB - We aimed to test the hypothesis that selenoprotein P (SELENOP), a hepatokine involved in the development of both insulin resistance and impaired insulin production in mice, is related to future onset of hyperglycemia in humans. 76 healthy non-pregnant human subjects without diabetes underwent oral glucose tolerance test (OGTT) at baseline and 4-years follow-up. Nine subjects developed either impaired glucose tolerance or type 2 diabetes at follow-up. At baseline, SELENOP concentrations correlated negatively with insulinogenic index, but not with homeostasis model assessment-estimated insulin resistance (HOMA-IR). Multivariate analysis showed that baseline SELENOP predicted fasting plasma glucose at follow-up independently of the other parameters. The receiver operating characteristic (ROC) curve analysis showed that baseline concentrations of serum SELENOP, but not of selenium, were a reliable test to predict future onset of glucose intolerance. In conclusion, elevation of circulating SELENOP, but not of circulating selenium, was positively and independently associated with future onset of glucose intolerance in a general Japanese population.
UR - http://www.scopus.com/inward/record.url?scp=85056461810&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056461810&partnerID=8YFLogxK
U2 - 10.1038/s41598-018-35067-2
DO - 10.1038/s41598-018-35067-2
M3 - Article
C2 - 30425271
AN - SCOPUS:85056461810
VL - 8
JO - Scientific Reports
JF - Scientific Reports
SN - 2045-2322
IS - 1
M1 - 16727
ER -
